Medicine and Dentistry
Neuroinflammation
100%
Remyelination
100%
Nalfurafine
100%
Clinically Isolated Syndrome
100%
Multiple Sclerosis
44%
κ-Opioid Receptor
33%
Experimental Autoimmune Encephalomyelitis
33%
Demyelination
33%
Kappa Opiate Receptor
33%
3,4 Dichloro N Methyl N [2 (1 Pyrrolidinyl)cyclohexyl]benzeneacetamide
33%
Therapeutic Procedure
22%
Kappa Opiate Receptor Agonist
22%
Side Effect
22%
Cuprizone
22%
Diseases
11%
Immune Response
11%
Cognitive Defect
11%
Cell Invasion
11%
Physical Disability
11%
Degenerative Disease
11%
Immunocompetent Cell
11%
Immunity
11%
Cytotoxic T-Cell
11%
Disease Exacerbation
11%
T-Helper Cell
11%
Inflammation
11%
Myelin Sheath
11%
Pharmacology, Toxicology and Pharmaceutical Science
Demyelinating Disease
100%
Nervous System Inflammation
100%
Nalfurafine
100%
Multiple Sclerosis
44%
3,4 Dichloro N Methyl N [2 (1 Pyrrolidinyl)cyclohexyl]benzeneacetamide
33%
Demyelination
33%
Experimental Autoimmune Encephalomyelitis
33%
Kappa Opiate Receptor
33%
Side Effect
22%
Kappa Opiate Receptor Agonist
22%
Cuprizone
22%
Disease Exacerbation
11%
Cognitive Defect
11%
CD8 Antigen
11%
Physical Disability
11%
Disease
11%
Inflammation
11%
Degenerative Disease
11%
Myelin
11%
Neuroscience
Remyelinization
100%
Demyelinating Disease
100%
Kappa Opiate Receptor
83%
Multiple Sclerosis
66%
Experimental Autoimmune Encephalomyelitis
50%
Receptor Agonists
33%
Cognitive Disorders
16%
Neurodegenerative Disorder
16%
Myelin
16%
CD4
16%
CD8
16%
Cell Invasion
16%
T Cell
16%